Language challenges in the developing world

As biopharma makes up an increasing proportion of the global pharmaceutical market, so it will follow into the world's emerging economies too. The opportunities in these markets are well-known, but what are the risks and challenges involved in working in developing countries with unique cultures and little understanding of Western medical concepts.

In this article for European Biopharmaceutical Review, Conversis CEO Gary Muddyman outlines the key language issues for biopharma companies entering developing world markets.

Download a PDF to read the full text here: EBR_Conversis_PDF_2010.pdf